Preclinical research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Based on the size and histological staining characteristics of the fibrils, it is likely that at least in part they are composed of type III collagen (reticulin). An in vitro study with native collagen demonstrated that fibronectin binds to type III collagen rather than other types.
== Medical uses == Amitriptyline is indicated for the treatment of major depressive disorder, neuropathic pain, and for the prevention of migraine and chronic tension headache. It can be used for the treatment of nocturnal enuresis in children older than 6 after other treatments have failed.
Primarily through the suspension of Qatari liquefied natural gas (LNG) and the closure of the Strait of Hormuz, several publications including the BBC, PBS, Deutsche Welle, Euronews, Financial Times and Bruegel, along with banks and think tanks, have projected that the continent will enter an energy crisis in 2026 similar to the 2022 energy crisis that followed the War in Ukraine. The conflict coincided with historically low European gas storage levels – estimated at just 30% capacity following a harsh 2025–2026 winter – causing Dutch TTF gas benchmarks to nearly double to over €60/MWh by mid-March. On 26 March, the European Commission advised its member states to fill their gas storages early to avoid price spikes later in the year.
From 2006 to 2013, Morgan was a cast member of the television series 30 Rock. He played the character Tracy Jordan, a caricature of himself. His work on 30 Rock was well-received, and he was nominated for Outstanding Supporting Actor in a Comedy Series at the 2009 Emmy Awards. He returned to the role in July 2020 for a reunion episode during the COVID-19 pandemic that was an upfront special for NBCUniversal. After 30 Rock, beginning in 2018, Morgan began starring in the TBS series The Last O.G. It ran for four seasons until 2021. Morgan also returned to host SNL on March 14, 2009, and reprised his roles as Brian Fellow and Astronaut Jones. He later made a guest appearance on the 2011 Christmas show, hosted by Jimmy Fallon, and again hosted the show on October 17, 2015. In addition to his television and comedy career, Morgan has acted in several comedy movies, alongside Adam Sandler, Eddie Murphy, and Will Ferrell. In Adam Sandler's film The Longest Yard, he plays a transgender inmate. He has also taken on a number of voice acting roles. He plays Spoonie Luv on the Comedy Central program Crank Yankers and as Woof in the animated series Where My Dogs At?. He also was the voice of Luis in the animated film Rio. Morgan has had a number of solo stand-up specials produced throughout his career. One Mic was produced and aired on Comedy Central in 2002. His other comedy specials include Tracy Morgan: Bona Fide in 2014 and Staying Alive in 2017, released after he was severely injured in a 2014 car accident.
Sources: en.wikipedia.org
They rendezvous with local Interpol agent Gail Runciter and proceed to the safehouse, where an elderly Zola, in a wheelchair and requiring an oxygen mask, seemingly overpowers Kate Neville's telepathy with his evil visions of destruction. Runciter lures Fury away from the group and shocks him with a device before revealing herself to be Viper in disguise. She then kisses Fury with poisoned lipstick, leaving him unconscious, enabling Hydra to retake Zola. Fury learns he has 48 hours to live unless he can recover a sample of Viper's DNA from which to develop an antidote. Hydra threatens to attack Manhattan with the virus, barring payment of US $1 billion, and as proof of their threat, the real Gail Runciter is found, dying from the virus. After Fury and his team brief the President of the United States, Pierce determines from a chip from a laptop sold in the Aleutian Islands that the Hydra base might be there. Fury has his people split into two teams, one led by de Fontaine heading to Manhattan to find the refrigerated truck they believe will be needed to deploy the virus, and the other with Fury leading Pierce and Neville to the Aleutian Islands. Upon arriving in the Aleutian Islands and confirming that a Hydra transmission has come from there, Fury's plane is shot down by heat-seeking missiles. In Manhattan, de Fontaine's team figures out that the refrigerator truck is disguised as a garbage truck, while Fury and his team, having bailed out of the airplane in time, infiltrate the Hydra base.
The middle layer of the heart wall is the myocardium, which is the cardiac muscle—a layer of involuntary striated muscle tissue surrounded by a framework of collagen. The cardiac muscle pattern is elegant and complex, as the muscle cells swirl and spiral around the chambers of the heart, with the outer muscles forming a figure 8 pattern around the atria and around the bases of the great vessels and the inner muscles, forming a figure 8 around the two ventricles and proceeding toward the apex. This complex swirling pattern allows the heart to pump blood more effectively. There are two types of cells in cardiac muscle: muscle cells which have the ability to contract easily, and pacemaker cells of the conducting system. The muscle cells make up the bulk (99%) of cells in the atria and ventricles. These contractile cells are connected by intercalated discs which allow a rapid response to impulses of action potential from the pacemaker cells. The intercalated discs allow the cells to act as a syncytium and enable the contractions that pump blood through the heart and into the major arteries. The pacemaker cells make up 1% of cells and form the conduction system of the heart. They are generally much smaller than the contractile cells and have few myofibrils which gives them limited contractibility. Their function is similar in many respects to neurons. Cardiac muscle tissue has autorhythmicity, the unique ability to initiate a cardiac action potential at a fixed rate—spreading the impulse rapidly from cell to cell to trigger the contraction of the entire heart.
According to these principles, there must exist in space megastructures of great size, emitting a lot of energy and information, and existing for billions of years, while being compact enough to rapidly exchange large amounts of data between them. A supercivilization would thus create a technological structure of cosmic dimensions. As an example, Kardashev cites Freeman Dyson's megastructure, in the form of a sphere of several astronomical units in diameter. Other phenomena may indicate highly technological activities, such as artificially exploding stars or the changing of stellar orbits to store mass and energy. Giant molecular clouds also hold great potential for astroengineering. Kardashev even raises the possibility of a supercivilization reshaping the entire galaxy. Then he evokes the theoretical and mathematical possibility of the existence of a megastructure in the form of a disk rotating on itself at a constant angular velocity. According to him, the search for intelligent signals should be directed to the detection of such megastructures at the characteristic radiation (20 μm). Quasars or galactic centers can be excellent candidates to testify to the existence of a supercivilization since they emit strong infrared radiation, which indicates a solid structure. The astronomer advises to look for these objects in a wavelength range from a few microns to a few millimeters. Large intelligent structures can also be detected by the fact that they screen or reflect the surrounding radiation.
Sources: en.wikipedia.org
gamete A haploid cell that is the meiotic product of a progenitor germ cell and the final product of the germ line in sexually reproducing multicellular organisms. Gametes are the means by which an organism passes its genetic information to its offspring; during fertilization, two gametes (one from each parent) are fused into a single diploid zygote.
== Legislation == The plight of patients with rare diseases became an important political issue in the late 1970s and early 1980s. The US government was subject to pressure from activist groups such as NORD and many others. The chief sponsor of the bill (H.R. 5238) was Henry Waxman (sometimes referred to as the author of the Act), chairman of the Energy and Commerce Subcommittee on Health. It passed the House of Representatives on 14 December 1982, and was similarly approved by voice vote in the Senate on 17 December. On 4 January 1983, President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA. Market exclusivity is particularly appealing to pharmaceutical firms as an incentive to pursue orphan drug development.
To perform a manual white blood cell differential, the microscopist counts 100 cells on the blood smear and classifies them based on their appearance; sometimes 200 cells are counted. This gives the percentage of each type of white blood cell, and by multiplying these percentages by the total number of white blood cells, the absolute number of each type of white cell can be obtained. Manual counting is subject to sampling error because so few cells are counted compared with automated analysis, but it can identify abnormal cells that analyzers cannot, such as the blast cells seen in acute leukaemia. Clinically significant features like toxic granulation and vacuolation can also be ascertained from microscopic examination of white blood cells. The hematocrit can performed manually by filling a capillary tube with blood, centrifuging it, and measuring the percentage of the blood that consists of red blood cells. This is useful in some conditions that can cause automated hematocrit results to be incorrect, such as polycythemia (a highly elevated red blood cell count) or severe leukocytosis (a highly elevated white blood cell count, which interferes with red blood cell measurements by causing white blood cells to be counted as red cells).
==== Never marketed ==== Alaproclate (GEA-654) Cericlamine (JO-1017) Desmethylcitalopram Didesmethylcitalopram Femoxetine (FG-4963; Malexil) Ifoxetine (CGP-15,210-G) Omiloxetine Panuramine (WY-26,002) Pirandamine (AY-23,713) RTI-353 Seproxetine ((S)-norfluoxetine)
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.